Analyst Mike Kratky of Leerink Partners reiterated a Hold rating on Edwards Lifesciences, boosting the price target to $83.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mike Kratky’s rating is based on a combination of factors that suggest a cautious outlook for Edwards Lifesciences in the near term. The MEDACorp U.S. TAVR survey indicates that the company’s U.S. TAVR sales for the second quarter of 2025 are expected to be slightly below consensus estimates, with a projected sales figure of $685 million, which is 1% less than the consensus of $692 million. This suggests that the company’s performance may not meet market expectations in the short term.
Despite some positive developments, such as the approval of SAPIEN M3 and potential catalysts like the reopening of the TAVR NCD, the survey results imply that Edwards Lifesciences may experience flat quarter-over-quarter sales growth. Additionally, there is a concern about potential market share erosion and modest growth in TAVR procedure volumes. These factors contribute to a more cautious stance on the stock, leading to the Hold rating as the company navigates these near-term challenges.
In another report released on July 9, Canaccord Genuity also maintained a Hold rating on the stock with a $75.00 price target.